Supplementary Table 2 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Zhewei Tang,Mingqian Feng,Wei Gao,Yen Phung,Weizao Chen,Amit Chaudhary,Brad St. Croix,Min Qian,Dimiter S. Dimitrov,Mitchell Ho

DOI: https://doi.org/10.1158/1535-7163.22497754

2023-01-01

Abstract:PDF file - 57K, The number of mesothelin sites per cell on cancer cell lines.

What problem does this paper attempt to address?

Supplementary Figure 1 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Zhewei Tang,Mingqian Feng,Wei Gao,Yen Phung,Weizao Chen,Amit Chaudhary,Brad St. Croix,Min Qian,Dimiter S. Dimitrov,Mitchell Ho

DOI: https://doi.org/10.1158/1535-7163.22497757

2023-01-01

Abstract:PDF file - 1308K, Production and analysis of the SD1-based recombinant immunotoxin.
Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Inna Smalley,Zhihua Chen,Manali S. Phadke,Jiannong Li,Xiaoqing Yu,Clayton Wyatt,Brittany Evernden,Jane L. Messina,Amod A. Sarnaik,Vernon K. Sondak,Chaomei Zhang,Vincent Law,Nam Tran,Arnold Etame,Robert J.B. Macaulay,Zeynep Eroglu,Peter Forsyth,Paulo C. Rodríguez,Yigiang Chen,Keiran S.M. Smalley

DOI: https://doi.org/10.1158/1078-0432.22481007.v1

2023-01-01

Abstract:Supplemental Table 1: Flow Cytometry Antibodies
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503681

2023-01-01

Abstract:PDF - 79K, Supplementary Table 2. Sensitivities of L3.6pl cells, CSCs+24/44/ESA and their derived polyploid cells in response to different chemotherapeutics.
Supplementary Tables 1 and 2 from ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin

Tiansuo Zhao,Wenna Jiang,Xiuchao Wang,Hongwei Wang,Chen Zheng,Yang Li,Yan Sun,Chongbiao Huang,Zhi-bo Han,Shengyu Yang,Zhiliang Jia,Keping Xie,He Ren,Jihui Hao

DOI: https://doi.org/10.1158/0008-5472.22416789.v1

2023-01-01

Abstract:Supplementary Table 1. Antibodies and primers Supplementary Table 2. Clinicopathologic characteristics of TMA
Supplementary Table 1 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Weibin Zou,Huilin Zheng,Tong-Chuan He,Jinjia Chang,Yang-Xin Fu,Weimin Fan

DOI: https://doi.org/10.1158/0008-5472.22392848

2023-01-01

Abstract:PDF file - 64K, MSC-L can exert therapeutic effect to inhibit tumor growth and induce immune
Supplementary Table 1 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394709

2023-01-01

Abstract:PDF file - 66K, Detailed information for the adult somatic tissues and cancer tissues from the five Affymetrix U133 plus2 gene expression datasets compiled for HEPA analysis
Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461188

2023-01-01

Abstract:Complete information of the detected peptides for the six bands of I and II by mass spectrometry.
Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503678.v1

2023-01-01

Abstract:PDF - 64K, Supplementary Table 3. Minimum Inhibitory Concentrations* of BMS-777607 and Chemoagents in L3.6pl Cells and L3.6pl Cell-Derived CSCs+24/44/ESA.
Supplementary Table 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Hongkui Jin,Renhui Yang,Zhong Zheng,Mally Romero,Jed Ross,Hani Bou-Reslan,Richard A.D. Carano,Ian Kasman,Elaine Mai,Judy Young,Jiping Zha,Zemin Zhang,Sarajane Ross,Ralph Schwall,Gail Colbern,Mark Merchant

DOI: https://doi.org/10.1158/0008-5472.22373637

2023-01-01

Abstract:Supplementary Table 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
Table S1 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Jing Shi,Tao Jiao,Qian Guo,Weining Weng,Linjie Ma,Qing Zhang,Lijun Wang,Jianjian Zhang,Caiwei Chen,Yaling Huang,Mingqiao Wang,Rong Pan,Yanfang Tang,Wenhao Hu,Tao Meng,Shu-Hui Liu,Jun Guo,Yan Kong,Xun Meng

DOI: https://doi.org/10.1158/0008-5472.24564639

2023-01-01

Abstract:TK parameters of Non-GLP toxicity studies in monkeys
Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399923.v1

2023-01-01

Abstract:PDF file - 71KB, Supplementary Table 1 Characteristics of 7 types of cancer patient in cancer survey array. Supplementary Table 2 Characteristics of patient in melanoma RNA chip. Supplementary Table 3 Characteristics of patient in melanoma IHC chip. Supplementary Table 4. Characteristics of patient in flow cytometry analysis.
Supplementary Table 5 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394694

2023-01-01

Abstract:PDF file - 56K, Age and sex distribution of the lung patient and healthy cohorts, and the autoantibody responses in lung cancer patients at different clinical stages
Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461191.v1

2023-01-01

Abstract:Relationship between expression levels of the BCMab1 epitope and clinicopathological features of human bladder cancers.
Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399947.v1

2023-01-01

Abstract:PDF file - 31KB, Supplementary Figure 2 Determination of concentration of IL-6 and IL-10 within tumor.
Mesothelin as a target for cervical cancer therapy

Korinna Jöhrens,Lea Lazzerini,Jana Barinoff,Jalid Sehouli,Guenter Cichon

DOI: https://doi.org/10.1007/s00404-018-4933-z

Abstract:Purpose: The cell surface glycoprotein Mesothelin is overexpressed in several tumor entities and novel immune-based therapies are currently under the early clinical evaluation for the treatment of malignant pleura mesothelioma, ovarian cancer, and pancreatic cancer. Cervical cancer has not been recognized as a suitable target for Mesothelin-directed immune therapies so far. Methods: To exploit a possible role of Mesothelin in cervical cancer treatment, we analysed Mesothelin expression in 79 cervical carcinomas and aligned expressions patterns with tumor growth parameters. A novel anti-Mesothelin drug conjugate (Anetumab Ravtansine) was applied for dose-efficiency studies in a Mesothelin positive tumor model for cervical cancer in Scid mice. Results: In more than three-quarters (77%) of cervical adenocarcinomas, Mesothelin was expressed to high levels. Among squamous cell carcinomas of the cervix uteri expression levels were lower and expression patterns were less intense, but still ranged between 50-60% (57%). A significant correlation between Mesothelin expression levels and tumor grade, metastatic behaviour, and lymph- or hemangiosis was not found. The novel anti-Mesothelin-drug conjugate (Anetumab Ravtansine) showed a substantial dose-dependent therapeutic efficiency in a xenotransplant model for cervical cancer in SCID mice (hela cell tumors). Applying the ADC at a dose of 10 mg/kg twice weekly induced complete tumor regression in 88% of animals within 6 weeks. Conclusions: Mesothelin should be taken into account as a target in cervical cancer therapy and histological determination of Mesothelin expression should be considered in routine diagnostics of cervical carcinomas.
Supplementary Table 3 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Qing-Wen Xu,Wei Zhao,Yue Wang,Maureen A. Sartor,Dong-Mei Han,Jixin Deng,Rakesh Ponnala,Jiang-Ying Yang,Qing-Yun Zhang,Guo-Qing Liao,Yi-Mei Qu,Lu Li,Fang-Fang Liu,Hong-Mei Zhao,Yan-Hui Yin,Wei-Feng Chen,Yu Zhang,Xiao-Song Wang

DOI: https://doi.org/10.1158/0008-5472.22394703

2023-01-01

Abstract:PDF file - 104K, Literature references reporting the clinical applications of known TSAs and the top 100 genes nominated by HEPA analysis
Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Tobias Schatton,Ute Schütte,Natasha Y. Frank,Qian Zhan,André Hoerning,Susanne C. Robles,Jun Zhou,F. Stephen Hodi,Giulio C. Spagnoli,George F. Murphy,Markus H. Frank

DOI: https://doi.org/10.1158/0008-5472.22384284.v1

2023-01-01

Abstract:Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells
Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

Chong Li,Zhao Yang,Ying Du,Haidong Tang,Jun Chen,Deqing Hu,Zusen Fan

DOI: https://doi.org/10.1158/1078-0432.22461185

2023-01-01

Abstract:Complete information of the detected glycans by glycochip assay.

Supplementary Table 2 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Supplementary Figure 1 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Tables 1 and 2 from ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin

Supplementary Table 1 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Table 1 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Table 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Table S1 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Table 5 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Mesothelin as a target for cervical cancer therapy

Supplementary Table 3 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 2 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Supplementary Figure 1 from A Human Single-Domain Antibody Elicits Potent Antitumor Activity by Targeting an Epitope in Mesothelin Close to the Cancer Cell Surface

Supplementary Table 1 from Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Tables 1 and 2 from ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin

Supplementary Table 1 from LIGHT Delivery to Tumors by Mesenchymal Stem Cells Mobilizes an Effective Antitumor Immune Response

Supplementary Table 1 from An Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens as Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Table 1 from MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

Table S1 from A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody–Drug Conjugate for Targeting Melanoma

Supplementary Tables 1 - 4 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplementary Table 5 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Mesothelin as a target for cervical cancer therapy

Supplementary Table 3 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 2 from Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells

Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Table 3 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 2 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>

Supplementary Table 4 from BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin α3β1, Has Potent Antitumor Activity of Bladder Cancer <i>In Vivo</i>